IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 88.75

Change

+1.68 (+1.93)%

Market Cap

N/A

Volume

0.24M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+2.32 (+1.66%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+1.16 (+1.74%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+1.54 (+1.42%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.95 (+2.11%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.57 (+2.60%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.88 (+2.83%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+2.59 (+2.69%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+1.15 (+3.91%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.37 (+2.27%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.63 (+2.91%)

USD 8.55M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

-0.79 (-0.57%)

USD 1.40B
XHC:CA iShares Global Healthcare.. 99.89 % 0.65 %

+0.85 (+-0.57%)

CAD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.23% 38% F 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.23% 38% F 60% D-
Trailing 12 Months  
Capital Gain 0.48% 24% F 33% F
Dividend Return 1.46% 88% B+ 23% F
Total Return 1.93% 29% F 24% F
Trailing 5 Years  
Capital Gain 25.92% 57% F 63% D
Dividend Return 7.76% 79% B- 22% F
Total Return 33.68% 71% C- 58% F
Average Annual (5 Year Horizon)  
Capital Gain 5.64% 67% D+ 53% F
Dividend Return 6.59% 67% D+ 48% F
Total Return 0.96% 74% C 24% F
Risk Return Profile  
Volatility (Standard Deviation) 13.20% 81% B- 71% C-
Risk Adjusted Return 49.97% 81% B- 64% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike